Overall negative Life Sciences Sentiments recorded in August 2022

The FCF Life Sciences team continuously analyses the current sentiments in the European life sciences venture capital funding sector.

For August ’22, venture capital funding continues to decline. All life sciences subsectors (i.e. Biotech, HealthTech, and MedTech) are currently affected.

According to our analysis, we expect this downward trend to persist in the coming months.

About FCF Life Sciences

FCF Life Sciences advises leading healthcare companies in Europe on financing transactions (equity, debt, and licensing) with regional and international investors. Our team consists of science-driven industry and finance experts with a strong track record in managing financing processes. We thrive to maximize the efficiency in the fundraising process and increase its closing probability.

Learn more about FCF Life Sciences, click here.

We closely track the activity in the financial markets and are passionate about capital markets research. Not every idea or research question make it into the final selection for our publications. However, we generate interesting information on financing trends in Life Sciences sector, which we would like to share in our blog.

To hear from us on the latest insights, please sign up here: